Add a GLP-1 Receptor Agonist
For a patient with type 2 diabetes, heart failure, and CKD already on dapagliflozin (Farxiga), add a long-acting GLP-1 receptor agonist—specifically dulaglutide, liraglutide, or injectable semaglutide—as these agents have proven cardiovascular benefits and require no dose adjustment in CKD. 1
Rationale for GLP-1 Receptor Agonist Addition
The 2022 ADA/KDIGO consensus explicitly states that for patients with T2D and CKD requiring additional glucose-lowering agents beyond metformin and SGLT2 inhibitors, a long-acting GLP-1 receptor agonist is the preferred choice 1. This recommendation is based on:
- Cardiovascular protection: GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) by 12%, cardiovascular death by 12%, and heart failure hospitalization by 9% in meta-analyses of cardiovascular outcomes trials 1
- Renal benefits: They reduce albuminuria and slow eGFR decline, with a 17% reduction in composite kidney outcomes 1
- Synergistic mechanisms: GLP-1 RAs work through completely different pathways than SGLT2 inhibitors, providing additive benefits without overlapping side effects 2
Specific Agent Selection
Choose one of these three GLP-1 receptor agonists with documented cardiovascular benefits:
- Dulaglutide: No dose adjustment required regardless of eGFR; can be used even with eGFR >15 mL/min/1.73 m² 1
- Liraglutide: No dose adjustment required; FDA-approved to reduce cardiovascular death, MI, and stroke in T2D with established CVD 3
- Injectable semaglutide: No dose adjustment required; demonstrated MACE reduction in cardiovascular outcomes trials 1
Avoid exenatide in advanced CKD (use not recommended with eGFR <30 mL/min/1.73 m²) and avoid lixisenatide in stage 4 CKD 1.
Dosing Strategy to Minimize Side Effects
Start low and titrate slowly to reduce gastrointestinal side effects 3:
- Dulaglutide: Start 0.75 mg weekly, can increase to 1.5 mg weekly
- Liraglutide: Start 0.6 mg daily, titrate by 0.6 mg increments weekly to 1.8 mg daily or maximally tolerated dose
- Semaglutide: Start 0.25 mg weekly, titrate slowly per prescribing information
Additional Considerations Based on Patient Profile
If Additional Glycemic Control Still Needed After GLP-1 RA:
The KDIGO 2020 guidelines provide a clear hierarchy 4:
DPP-4 inhibitors (if not already on GLP-1 RA, as they should not be combined)
- Linagliptin requires no dose adjustment
- Sitagliptin: reduce to 50 mg daily if eGFR 30-44,25 mg if eGFR 15-29
Insulin (titrate conservatively to avoid hypoglycemia in CKD)
Other options (lower priority): sulfonylureas (use glipizide or glimepiride cautiously, avoid glyburide), thiazolidinediones (may worsen fluid retention in heart failure—use with extreme caution)
Critical Safety Points
Monitor for hypoglycemia risk: If the patient is on insulin or sulfonylureas when adding GLP-1 RA, you may need to reduce those doses to prevent hypoglycemia 4
Heart failure considerations: GLP-1 receptor agonists are safe in heart failure and reduce HF hospitalizations 1. Unlike thiazolidinediones, they do not cause fluid retention.
CKD-specific benefits: The MACE risk reduction with liraglutide was significantly greater in patients with eGFR <60 mL/min/1.73 m² compared to those with preserved kidney function 1, making this an ideal population for GLP-1 RA therapy.
What About Metformin?
If the patient is not already on metformin and has eGFR ≥30 mL/min/1.73 m², add metformin as well 5, 4. Most patients with T2D and CKD benefit from both metformin and an SGLT2 inhibitor as foundational therapy 4. Adjust metformin dose if eGFR <45 mL/min/1.73 m² (reduce to 1000 mg/day if eGFR 30-44) 1.
Emerging Option: Finerenone
Consider adding finerenone (a non-steroidal mineralocorticoid receptor antagonist) if the patient has significant albuminuria (UACR ≥30 mg/g), as it provides additional cardiorenal protection beyond SGLT2 inhibitors and GLP-1 RAs 5. The FIDELIO-DKD trial showed 18% reduction in the composite kidney outcome and 14% reduction in cardiovascular events. Monitor potassium closely (2.3% discontinued due to hyperkalemia vs 0.9% with placebo) 5.